E. Bendstrup (Vejle, Denmark), J. Wälscher (Essen, Germany), C. Moor (Rotterdam, Netherlands), C. Vancheri (Catania (CT), Italy)
Late Breaking Abstract - Calpain regulates epithelial-mesenchymal transition and its correlation with Akt signaling in pulmonary fibrosis. Y. Liu (Wuhan, China), B. Liu (Wuhan, China), J. Zou (Wuhan, China), M. Zou (Wuhan, China), Z. Cheng (Wuhan, China)
| |
Prognostic and functional significance of osteoporosis and vitamin D deficiency in interstitial lung diseases V. Somogyi (Heidelberg, Germany), C. Silva (Heidelberg, Germany), S. Triphan (Heidelberg, Germany), M. Eichinger (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany)
| |
Depression is a predominant symptom among hypogonadism male patients with Interstitial Pulmonary Fibrosis D. Magdy (Egypt, Egypt), a. metwally (Department: Chest, Faculty of Medicine, Assiut University , Egypt), R. El Zohne (Egypt, Egypt)
| |
Validity and responsiveness of the Euro-Qol-5 Dimensions-5 Levels (EQ5D5L) in IPF C. Nolan (London, United Kingdom), M. Maddocks (London, United Kingdom), T. Maher (London, United Kingdom), S. Jones (London, United Kingdom), S. Patel (London, United Kingdom), R. Barker (London, United Kingdom), P. George (London, United Kingdom), W. Man (London, United Kingdom)
| |
Prevalence and clinical relevance of comorbidities in IPF E. Puxeddu (Rome, Italy), L. Calzetta (Rome, Italy), A. Barrile (Rome, Italy), F. Cavalli (Rome, Italy), A. Sebastiani (Rome, Italy), M. Cazzola (Rome, Italy), P. Rogliani (Rome, Italy)
| |
Validation of the King’s Brief Interstitial Lung Disease questionnaire in Danish T. Skovhus Prior (Aarhus, Denmark), O. Hilberg (Vejle, Denmark), S. Birring (London, United Kingdom), E. Bendstrup (Aarhus, Denmark)
| |
Vitamin D predicts disease progression in patients with pulmonary fibrosis and blunts in-vitro fibrotic responses V. Tzilas (Athens, Greece), A. Tzouvelekis (Athens, Greece), E. Bouros (Athens, Greece), T. Karampitsakos (Athens, Greece), S. Kourtidou (Athens, Greece), I. Barbayianni (Athens, Greece), I. Ninou (Athens, Greece), V. Aidinis (Athens, Greece), D. Bouros (Athens, Greece)
| |
Diagnosis and therapy of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) in Germany M. Polke (Heidelberg, Germany), J. Behr (München, Germany), H. Kabitz (Konstanz, Germany), C. Neurohr (München, Germany), G. Leuschner (München, Germany), A. Prasse (Hannover, Germany), F. Bonella (Essen, Germany), D. Koschel (Coswig, Germany), J. Waelscher (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany)
| |
Evaluation of Dyspnea Questionnaires in Patients with Idiopathic Pulmonary Fibrosis (IPF). O. Moran Mendoza (Kingston, ON, Canada), S. Aldaheri (Kingston, ON, Canada), S. Alyami (Kingston, ON, Canada), M. Kish (Kingston, ON, Canada), S. Davison (Kingston, ON, Canada)
| |
Prognostic impact of the pulmonary artery size on chest computed tomography in Idiopathic Pulmonary Fibrosis patients J. Choi (Seoul, Republic of Korea), S. Moon (Seoul, Republic of Korea), S. Kwak (Seoul, Republic of Korea), J. Shin (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea)
| |
Different characteristics and outcomes of acute exacerbation: comparison between interstitial pneumonia with autoimmune features and lone idiopathic interstitial pneumonia. R. Mori (Kobe, Japan), M. Kogo (Kobe, Japan), K. Hosoya (Kobe, Japan), H. Kawachi (Kobe, Japan), R. Hirabayashi (Kobe, Japan), M. Ito (Kobe, Japan), D. Fujimoto (Kobe, Japan), K. Nagata (Kobe, Japan), R. Tachikawa (Kobe, Japan), A. Nakagawa (Kobe, Japan), K. Otsuka (Kobe, Japan), K. Tomii (Kobe, Japan)
| |
Modified GAP stage as a predictor of acute exacerbation in idiopathic pulmonary fibrosis S. Ohshimo (Hiroshima, Japan), Y. Kida (Hiroshima, Japan), M. Kyo (Hiroshima, Japan), Y. Horimasu (Hiroshima, Japan), S. Miyamoto (Hiroshima, Japan), H. Iwamoto (Hiroshima, Japan), H. Hamada (Hiroshima, Japan), N. Hattori (Hiroshima, Japan), F. Bonella (Essen, Germany), J. Guzman (Bochum, Germany), U. Costabel (Essen, Germany), N. Shime (Hiroshima, Japan)
| |
Prevalence of cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study A. Tzouvelekis (Athens, Greece), T. Karampitsakos (Athens, Greece), G. Gomatou (Athens, Greece), V. Tzilas (Athens, Greece), E. Bouros (Athens, Greece), S. Chrysikos (Athens, Greece), E. Markozannes (Athens, Greece), L. Kolilekas (Athens, Greece), E. Manali (Athens, Greece), I. Tomos (Athens, Greece), I. Korbila (Athens, Greece), P. Tomos (Athens, Greece), K. Loverdos (Athens, Greece), A. Gaga (Athens, Greece), K. Antoniou (Heraklion, Greece), A. Trachalaki (Heraklion, Greece), Z. Daniil (Larissa, Greece), F. Bardaka (Larissa, Greece), K. Markopoulou (Thessaloniki, Greece), S. Papiris (Athens, Greece), R. Tringidou (Athens, Greece), D. Bouros (Athens, Greece)
| |
Hospitalisation pattern in Interstitial Lung Diseases: a claims data study S. Witt (München, Germany), J. Waelscher (Heidelberg, Germany), L. Schwarzkopf (München, Germany), M. Kreuter (Heidelberg, Germany)
| |
Diaphragm dysfunction in combination with lung function decline is associated with higher mortality in idiopathic pulmonary fibrosis patients E. Barczi (Budapest, Hungary), A. Farkas (Budapest, Hungary), A. Bohacs (Budapest, Hungary), K. Vincze (Budapest, Hungary), N. Eszes (Budapest, Hungary), G. Losonczy (Budapest, Hungary), V. Muller (Budapest, Hungary)
| |
Natural history of idiopathic pulmonary fibrosis (IPF) associated with obstructive sleep apnea (OSA) with or without continuous positive airway pressure (CPAP) T. Gille (Bobigny, France), M. Didier (Bobigny, France), M. Boubaya (Bobigny, France), Z. Carton (Bobigny, France), D. Sadoun-Danino (Bobigny, France), D. Israël-Biet (Paris, France), V. Cottin (Lyon, France), F. Gagnadoux (Angers, France), B. Crestani (Paris, France), M. D'Ortho (Paris, France), P. Brillet (Bobigny, France), D. Valeyre (Bobigny, France), H. Nunes (Bobigny, France), C. Planès (Bobigny, France)
| |
Application of a predictive formula for hypoxic challenge testing in patients with interstitial lung disease S. Patel (London, United Kingdom), R. Hastings (London, United Kingdom), H. Lota (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), G. Magaritopoulos (London, United Kingdom), V. Kouranos (London, United Kingdom), M. Kokosi (London, United Kingdom), T. Maher (London, United Kingdom), A. Wells (London, United Kingdom), P. George (London, United Kingdom), E. Renzoni (London, United Kingdom)
| |
The role of infection in acute exacerbation of Idiopathic Pulmonary Fibrosis D. Weng (Shanghai, China), H. Li (Shanghai, China)
| |
Does body mass index influence survival of patients with idiopathic pulmonary fibrosis? N. Mogulkoc (Izmir, Turkey), B. Uysaler (Izmir, Turkey), P. Bishop (Manchester, United Kingdom)
| |
Comorbid conditions in IPF patients; their frequencies and impacts on survival A. Koc (Izmir, Turkey), N. Mogulkoc (Izmir, Turkey), P. Bishop (Manchester, United Kingdom)
| |